COVID-19: A Systematic Review of Chinese Clinical Guidelines
Author(s)
ABSTRACT WITHDRAWN
Presentation Documents
OBJECTIVES China employed strict confinement strategies and effective disease management to control the spread of coronavirus disease (COVID-19). This study summarized and evaluated the Chinese guidelines related to COVID-19 to learn from their experiences in the fight against the COVID-19 pandemic. METHODS A systematic search of the China National Knowledge Infrastructure (CNKI) database, Yimaitong database, and World Health Organization (WHO) COVID-19 database was conducted on March 20th, 2020 to identify Chinese guidelines relevant to COVID-19. A comprehensive description was provided on the general information of guidelines (e.g., publication agencies and target population), complemented with the recommendations on pharmacological treatments. RESULTS : A total of 114 guidelines were identified, including 87 national guidelines and 27 regional guidelines. The included guidelines focused on the prevention and control measurements, as well as clinical diagnosis and treatment strategies of COVID-19. Sixty-four guidelines targeted general COVID-19 patients, and the rest 50 guidelines focused on specific populations, such as pediatric population, geriatric population, and patients with comorbidities. Twenty-three guidelines proposed recommendations for pharmacological treatments. Interferon, lopinavir/ritonavir, ribavirin, chloroquine (CQ), and umifenovir were mainstream medical therapies being most recommended in the included guidelines. CQ, as one of the drugs generating lots of discussions, has been first recommended in the 6th version of National Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia. Thereafter, the detailed instructions on dosage adjustment and adverse events management of CQ have also been updated in subsequent 7 Chinese guidelines with the accumulations of preclinical and preliminary clinical evidence. CONCLUSIONS : During COVID-19 pandemic, China proactively generated guidelines addressing all aspects of COVID-19 management. Such endeavors secured China to react and coordinate all the available resources to cope with COVID-19 promptly and efficiently. These guidelines may have been insufficiently disseminated but led to widening CQ use across the world.
Conference/Value in Health Info
2020-11, ISPOR Europe 2020, Milan, Italy
Value in Health, Volume 23, Issue S2 (December 2020)
Code
PDG52
Topic
Clinical Outcomes, Epidemiology & Public Health, Health Policy & Regulatory, Health Service Delivery & Process of Care
Topic Subcategory
Clinician Reported Outcomes, Disease Management, Health Disparities & Equity, Public Health
Disease
Drugs